Clinical bottom line
Polycystic ovary syndrome (PCOS) management continues to evolve with growing emphasis on individualized lifestyle interventions combined with pharmacotherapy. Weight management through diet and exercise remains foundational, improving metabolic and reproductive outcomes. Pharmacologic options, including insulin sensitizers and anti-androgens, are increasingly tailored based on patient phenotype and comorbidities. Emerging therapies targeting molecular pathways implicated in PCOS pathogenesis hold promise but require further validation. Multidisciplinary approaches integrating lifestyle modification, pharmacotherapy, and adherence support optimize patient outcomes (Escobar-Morreale et al., 2018; Panchpuri et al., 2026).
What the evidence shows
Escobar-Morreale et al. (2018) provide a comprehensive review of PCOS pathophysiology and treatment, underscoring lifestyle modification as first-line therapy. Weight loss of 5–10% can restore ovulation and improve insulin resistance. Exercise and dietary changes improve metabolic parameters independent of weight loss.
Jungari et al. (2023) highlight that combining pharmacotherapy with lifestyle interventions enhances symptom control and adherence. Metformin remains a mainstay for insulin resistance, while anti-androgens address hyperandrogenism. Newer agents under investigation include GLP-1 receptor agonists and inositols.
Panchpuri et al. (2026) discuss emerging therapeutics targeting inflammatory and hormonal pathways, reflecting advances in understanding PCOS heterogeneity. Single-cell profiling studies (Eriksson et al., 2025) reveal altered endometrial cell populations, suggesting potential for precision medicine approaches.
Islam et al. (2022) review genetic and environmental contributors to PCOS, reinforcing the need for personalized treatment plans that address lifestyle factors alongside pharmacologic options.
Caveats and uncertainty
Heterogeneity in PCOS phenotypes complicates standardized treatment algorithms.
Long-term safety and efficacy data for emerging pharmacotherapies are limited.
Adherence to lifestyle interventions remains a significant barrier in clinical practice.
Genetic and molecular insights have yet to translate into widely available targeted therapies.
Most evidence derives from observational studies or small trials; large randomized controlled trials are needed.
How this may change practice
Clinicians should prioritize individualized lifestyle counseling focusing on sustainable diet and exercise modifications.
Pharmacotherapy should be tailored to metabolic and reproductive phenotypes, with consideration of emerging agents as evidence evolves.
Enhanced adherence counseling and multidisciplinary care models may improve outcomes.
Integration of molecular diagnostics may eventually facilitate precision medicine in PCOS management.
Ongoing research will refine therapeutic options and inform guideline updates.